Universal Corporation — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2023, compared primarily with fiscal 2022. The request metadata says “2021 Q4,” but the filing provided is a FY2023 Form 10-K; it does not report a 2021 Q4 period.
Business context
Universal is a global business-to-business supplier of leaf tobacco and plant-based ingredients, operating in more than 30 countries. Tobacco remains its principal business; Ingredients includes fruit and vegetable products, botanical extracts, and flavorings. The company reported approximately $2.6 billion in fiscal 2023 revenue. Tobacco accounted for 88% of revenue and 94% of segment operating income.
Key financial results
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $2,569.8 million | $2,103.6 million | Up 22% |
| Gross margin | 17.83% | 19.44% | Down 161 bps |
| Operating income | $181.1 million | $160.3 million | Up 13% |
| Net income attributable to Universal | $124.1 million | $86.6 million | Up 43% |
| Diluted EPS | $4.97 | $3.47 | Up 43% |
| Adjusted diluted EPS (non-GAAP) | $3.77 | $3.79 | Down 1% |
| Operating cash flow | $(10.6) million | $44.9 million | Down $55.4 million |
Higher tobacco volumes and prices and the addition of Shank’s contributed to revenue growth. Cost of goods sold rose 25%, faster than revenue, reflecting higher raw-material costs and lower-margin tobacco sales. Interest expense increased to $49.3 million from $27.7 million, mainly due to higher debt balances and rates.
Tobacco segment revenue rose 23% to $2,258.3 million and operating income increased 10% to $172.9 million, supported by larger shipments, including carryover crops from Brazil. Ingredients revenue rose 16% to $311.6 million, but segment operating income fell 36% to $10.6 million amid higher overhead and capability-building costs, and softer demand and customer margin pressure in the second half.
Liquidity, debt and capital returns
- Year-end cash was $64.7 million; working capital was $1.36 billion and the current ratio was 4.08.
- Net debt increased $117.5 million to $750.7 million; net debt was approximately 35% of net capitalization, versus 32% a year earlier. Long-term debt was $616.8 million, with no long-term maturities until fiscal 2028.
- The company had $500 million available under its $530 million revolving facility and approximately $183 million of unused uncommitted credit lines. It reported compliance with debt covenants.
- Capital expenditures were $54.7 million. Management expects fiscal 2024 capital spending of approximately $65–$75 million, including investment in ingredients manufacturing capacity.
- Dividends and share repurchases returned $80.8 million to shareholders in FY2023. The annual dividend was $3.16 per share, and management announced a 53rd consecutive annual dividend increase in May 2023. A $100 million repurchase authorization remained available at year-end.
Material changes, outlook and unusual items
- Reported FY2023 earnings benefited materially from a final Brazilian tax ruling: $24.2 million net income tax benefit and $5.0 million interest income. The filing says the effective tax rate would have been approximately 25.5% without this ruling and the Tanzania sale-related tax item, versus the reported 8.3% rate.
- Reported diluted EPS was $4.97, while adjusted diluted EPS was $3.77; the difference principally reflects the favorable tax ruling and related interest. FY2022 adjusted EPS was $3.79, indicating broadly flat underlying adjusted EPS despite higher reported earnings.
- Management described tobacco supply as tight and industry uncommitted inventories as historically low. It forecast larger FY2024 flue-cured and burley crops than FY2023, but expected both to remain undersupplied relative to demand. African weather, including Cyclone Freddy, affected burley crop prospects.
- Management said improved logistics enabled substantial carryover tobacco shipments in FY2023. It characterized softer ingredients demand and customer margin pressure as temporary, attributing them to inventory adjustments and consumer-facing inflation pressures.
- The company continues to invest in integration and expansion of its plant-based ingredients platform. It also noted that long-term demand for leaf tobacco faces pressure from declining cigarette consumption and regulation; the effect of alternative tobacco products on leaf demand remains uncertain.
Risks and contingencies
- Customer concentration is significant: the seven largest tobacco customers represented more than 60% of consolidated revenue in each of the last three years; three customers individually exceeded 10% of FY2023 revenue.
- Seasonality, crop yields and quality, weather and climate exposure, shipment timing, transportation constraints, inflation, and foreign-exchange movements can affect margins, working capital and period-to-period results.
- Farmer and supplier advances were approximately $199 million gross, with a $24 million allowance. Recoverable VAT credits were approximately $64 million gross, with a $22 million allowance; both balances require estimates and judgments.
- Brazilian state VAT assessments remain contested. The filing reports possible losses of up to approximately $10 million for Santa Catarina and $3 million for Paraná; management considered losses not probable and recorded no liability.
- Other risks include tobacco regulation and taxation, international political and economic conditions, cybersecurity, food safety and supply-chain disruption in Ingredients, and acquisition integration. Management said ongoing litigation and tax matters were not expected to materially affect the business or financial position, while noting an adverse resolution could materially affect a reporting period.
- Ernst & Young issued unqualified opinions on the financial statements and internal controls. The audit identified advances to tobacco suppliers and recoverable VAT credits as critical audit matters due to estimation uncertainty.
Important facts for investors to verify
- How much FY2023 earnings and EPS depended on the Brazilian tax ruling, and the timing and practical realization of the tax credits.
- Whether FY2024 tobacco crop sizes, shipment timing and low uncommitted inventories support margins and cash conversion.
- Whether Ingredients demand and margins recover, and whether the planned capacity investment generates adequate returns.
- Working-capital requirements, operating cash flow, debt costs and covenant headroom as seasonal borrowing needs evolve.
- Developments in the disputed Brazilian VAT assessments, and recoverability of supplier advances and VAT credits.